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Summary
Objectives: To determine: (1) health-related quality of life (HRQL) in patients with severe osteoarthritis (OA) on a waiting list (WL) for total knee
replacement (TKR) and to compare it with general Spanish reference population values (RPVs); (2) the inﬂuence of sociodemographic and
clinical variables on HRQL dimensions and (3) the use and cost of resources related to knee OA.
Methods: Cross-sectional study. HRQL was measured by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and
Medical Outcomes Study 36 Item Short Form Health Survey (SF-36) questionnaires. Sociodemographic and disease characteristics, body
mass index, pharmacological treatment and the cost and use of economic resources related to knee OA during the 6-months previous to base-
line were recorded. Relationships were analyzed using linear regression models.
Results: One hundred consecutive outpatients (71 female, mean age 71 6.89 years, mean disease duration 11.84 10.52 years) were in-
cluded. Patients showed worse HRQL measured by SF-36 than the reference population, mainly in physical function, physical role and bodily
pain dimensions (P< 0.05). A low number of visits to physicians were recorded (mean 0.62 1.04). Total mean direct medical costs were
200.24 V (95%CI 167.08e233.40) and total mean direct non-medical costs were 1234.87 V (95%CI 812.74e1657.00).
Conclusions: The HRQL of patients on a WL is worse than that of the reference population. The main costs of these patients were on non-
medical resources, mainly due to functional limitations and loss of autonomy. The results suggest little compliance with knee OA management
guidelines.
ª 2006 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Studies have shown that health-related quality of life
(HRQL) measures, although not yet standardized, are valid,
reliable, and responsive for the evaluation of health results,
especially chronic processes1. HRQL can be measured by
generic and speciﬁc measures. These include, among
others, health proﬁles such as the Medical Outcomes Study
36 Item Short Form Health Survey (SF-36) general ques-
tionnaire2. In knee osteoarthritis (OA), the Western Ontario
and McMaster Universities Osteoarthritis Index is recom-
mended (WOMAC LK 3.0)3,4.
OA causes disability and limitation of activity, especially
when it affects load-bearing joints5,6. Total knee replace-
ment (TKR) is the treatment of choice in many cases, above
all in older people7. TKR is indicated to recover function in
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Received 16 May 2006; revision accepted 23 July 2006.patients with untreatable pain and/or severe disability
when conservative treatment does not yield acceptable
results8. However, in the Spanish National Health Service,
as in other nationalized health services, the demand for
this surgery means that delays occur, generating waiting
lists (WLs)9,10.
The unsatisfactory situation of patients on WL offers
the opportunity to monitor and observe the impact of knee
OA end stage disease on health results8 and the use of
health resources in these patients11. These aspects as-
sume a greater importance given the increasing number
of older people in our society12. Although the number of
reports on the health and economic impact of knee OA is
increasing11,12 there are few data on patients on WL.
The objectives of this study were: (1) to determine HRQL
in patients with OA grade IV on a WL for TKR and to com-
pare it with general Spanish reference population values
(RPVs); (2) to determine the inﬂuence of sociodemographic
and clinical variables on HRQL dimensions and (3) to ana-
lyze the use and cost of economic resources in relation to
knee OA.258
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SETTING
Cross-sectional study was carried out in the Rheumatol-
ogy Service and the Knee Unit of the Orthopaedic Surgery
Service of the Hospital Clı´nic Provincial (HCP), Barcelona
(Spain), a public tertiary care center. Patients were enrolled
between February and October 2001. Hospital Ethics
Committee approval was obtained.
PARTICIPANTS
The study population was 104 consecutive outpatients of
all ages diagnosed with knee OA grade IV (according to
Kellgren and Lawrence criteria)13, on a WL for TKR, for
less than 6 months, who agreed to participate and gave in-
formed consent. Exclusion criteria were: functional illiteracy;
inﬂammatory or other severe musculoskeletal conditions
(e.g., rheumatoid arthritis (RA), sciatica), metabolic or neo-
plastic disease and severe psychopathology or comorbidity,
deﬁned as a diagnosis in the medical record severe enough
that the patient could not participate fully in the study proce-
dures (e.g., heart failure).
VARIABLES DETERMINED
All variables were determined at study entry (baseline).
1) HRQL was measured by the self-reported Spanish
version of the SF-36 [Ref. 14] and the knee-speciﬁc ques-
tionnaire WOMAC LK 3.0 adapted to the Spanish popula-
tion15. The SF-36 has four physical and four mental health
dimensions, with scores ranging from 0 (worst) to 100
(best): physical function, social function, physical role limita-
tions, emotional role limitations, general mental health, en-
ergy, bodily pain, and general health perception. It allows
ageesex standardized comparisons to be made with
general Spanish RPVs4,14.
The SF-36 questionnaire also includes a self-perceived
health transition question: ‘‘Compared with 12 months
ago, how would you rate your general health now?’’ (not
used to score any of the eight multi-item scales). The
responses are: much better, somewhat better, about the
same, somewhat worse, and much worse2,14. The WOMAC
has three dimensions: pain, stiffness, and function. These
dimensions produce scores of 0e20, 0e8, and 0e68,
respectively, with higher scores indicating more pain and
stiffness, and worse physical function4,15.
2) A structured questionnaire collected information on (i)
sociodemographic and (ii) disease characteristics, pharma-
cological treatment and (iii) the use and cost of economic
resources related to knee OA during the 6-months previous
to baseline.
- Sociodemographic data included: gender, age, educa-
tional level, marital status, social support based on living
status, occupation, main type of job during working life
(standing, seated, or mixture of two), heavy lifting, occu-
pational situation and family income per year.
- Disease characteristics included: disease duration
(since diagnosis in years), time on WL for TKR (in
months), comorbidity (participants were asked if
they currently had, or if a physician ever told them that
they had any of the following medical comorbidities:
hypertension, cardiovascular disease, diabetes, respira-
tory disease, gastrointestinal disease, and problems ofhearing and vision); total number of reported comorbid-
ities which had persisted for more than 6 months; and
previous prostheses (contralateral knee, hip). Phar-
macological treatment included: the current number
of analgesics (paracetamol) and non-steroidal anti-
inﬂammatory drugs (NSAIDs) per week and other drugs
related to knee OA in tablets per week. Other questions
related to treatment were: satisfaction with current treat-
ment (yes/no) and common adverse events related with
knee OA treatment (nausea, diarrhea, heartburn, skin
eruptions, etc.).
- Self-reported use of economic resources during the 6
months previous to baseline included:
a) Weekly number of hours of formal or informal home
care by paid private household help or unpaid help
from family or relatives and out-of-pocket expenses
(prescriptions or taxis to attend medical visits).
b) Number of visits to general practitioners (GP), spe-
cialists (S), other health care professionals (e.g.,
physiotherapist, nurse practitioner, psychotherapist
and other) and alternative practitioners.
The cost of home adaptations, waiting time and travel to
health visits were not included.
All questionnaires were carried out in the hospital. An
independent researcher provided aid, if necessary, to
patients answering the questionnaires.
3) Body mass index (BMI), overweight and/or obesity
duration (since diagnosis in years) (<25 kg/m2 [BMI],
25e30 kg/m2 [overweight] and >30 kg/m2 [obesity])16
were determined.
4) Medical records and a systematic search of the central
HCP information system provided information on the use of
health resources related to knee OA during the 6 months
previous to baseline. We recorded the number of technical
procedures performed due to knee OA (conventional radio-
graphic examinations and all other technical procedures, in-
cluding computed tomography (CT) scan, and magnetic
resonance imaging); blood tests and non-pharmacological
treatments (number and duration of rehabilitation treat-
ments). In addition, data reported by patients on current
pharmacological treatment were conﬁrmed using the
primary care chronic medication system which records all
medication taken by primary care patients.
These data were reviewed by another independent
researcher.
ESTIMATE OF THE COST OF ECONOMIC RESOURCES
The costs of the economic resources used due to knee
OA were assessed as direct medical and non-medical costs
from a societal perspective, meaning that all relative costs
were taken into account regardless of the ﬁnancier17. The
Spanish National Health Service provides universal primary
and specialized care. All care, including tests and analyses,
is provided free. People aged 65 years receive free
medical prescriptions (all study subjects were aged 65
years).
a) Direct medical costs were considered as: visits to phy-
sicians (GP and S) or other health care professionals
and alternative practitioners; technical procedures
(medical devices); and pharmacological treatments
(number of analgesics, NSAIDs and other drugs taken
per week related to knee OA) and ancillary non-phar-
macological treatments.
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weekly number of hours of paid formal/informal home
care and out-of-pocket costs.
Unit prices for direct medical costs, including technical
procedures and blood tests, were calculated according to
2001 Catalan Health Service tariffs18 and pharmacological
treatments according to the Spanish National Pharmaco-
therapeutical Catalogue. If the cost of alternative practi-
tioners could not be ofﬁcially determined, the amount
speciﬁed by patients during the interview was considered
correct.
The market cost method, based on the assumption that
the salary reﬂected the marginal production value of
a worker, was used to quantify the cost of informal home
care19. Thus, it was assumed that the cost was equal to
the normal salary paid to a worker employed in home
care19 and was calculated as the average hourly cost of
a professional carer in Barcelona20. Therefore, the lost
salary of a family member (or other) in terms of informal
home care was valued at 7 euros per hour20.
Out-of-pocket expenses were quantiﬁed as the amount
speciﬁed during the interview that was spent on prescrip-
tions and taxi fares to attend medical visits.
All prices are expressed in 2001 euros (one
euro¼ $1.17). The accumulated increase in the retail price
index of Catalonia during the years 2001e2006 is 20%21.
Discounting was not relevant because of the limited time
horizon of the analysis17.
STATISTICAL ANALYSIS
Accepting an alpha risk of 0.5 for an estimated proportion
of 0.50 and a rate of loss of 10%, a minimum of 90 subjects
was required.
A descriptive analysis was performed using univariate fre-
quency tabulation for categorical variables or mean values
for continuous variables and conﬁdence intervals (CIs).
Mean SF-36 scores were compared with ageesex-matched
Spanish RPV14. Differences between study sample values
and Spanish RPV were analyzed using t tests.
Multiple linear regression models were used to analyze
the inﬂuence of sociodemographic and disease variables
(independent variables) on the dimensions of HRQL mea-
sured by SF-36 and WOMAC questionnaires (dependent
variables). Regression diagnostics for ordinary least-
squares regression (OLS) were conducted. Appropriate
transformations were applied to those variables not fulﬁlling
OLS assumptions. The variable pain (WOMAC) was con-
verted by logarithms (response¼ log( y)). Other variables
taking zero values were re-scaled using a power transforma-
tion (response¼ y1/a): physical function (a¼ 1.75), physical
role (a¼ 25), bodily pain (a¼ 1.5) and emotional role
(a¼ 0.33). Categorical variables were coded as dummies.
Variable selection was performed by combining the step-
wise and all subset regression methods. Model ﬁt is pre-
sented in the results using adjusted R2 and P-values for
signiﬁcance of regression coefﬁcients.
The relationship between costs and the other variables
studied was determined using Spearman’s correlation coef-
ﬁcient for continuous variables and the ManneWhitney test
or KruskaleWallis test for categorical variables of two or
more categories, respectively, as the distribution was not
normal. The inﬂuence of HRQL (SF-36 and WOMAC) on
costs was analyzed by linear regression. The CI was estab-
lished at 95%. A value of P< 0.05 was considered statisti-
cally signiﬁcant. The statistical analysis was performedusing the Statistical Package for Social Sciences (SPSS)
12.0 adapted to Windows.
Results
Of the 104 patients, four were excluded due to RA. Of the
100 patients analyzed, 71% were female. The mean age
was 71.2 (SD 6.9) years. Sixty-seven per cent lived with their
family. No patient was in paid employment. Mean disease
duration was 11.8 (SD 10.5) years. Current pharmacological
treatment was: weekly analgesics 5.3 (SD 9.7) tablets,
weekly NSAIDs 7.6 (SD 7.3) tablets, and weekly other drugs
2.6 (SD 4.7) tablets. Eighty-seven per cent of patients re-
ported one or more medical comorbidities (mean 1.79, SD
1.18). Sixty-three per cent were satisﬁed with current treat-
ment. The mean time on the WL at the study entry was
3.7 (SD 1.7) months. Family income was <6000 euros
39%, 6000e12,000 euros 50%, 12,000e18,000 euros 6%
and >18,000 euros 5%.
The eight dimensions of the SF-36 showed worse values
than the ageesex-matched Spanish population14. The phys-
ical function, physical role and bodily pain dimension scores
were >40% worse than RPV (Fig. 1). The SF-36 self-
perceived transition question showed that 55% of the pa-
tients reported feeling worse (33 patients) or much worse
(22 patients) than 1 year before. The mean scores of the
three WOMAC dimensions were: pain 10.78 (95%CI
9.98e11.58), stiffness 3.98 (95%CI 3.54e4.41) and function
39.65 (95%CI 37.13e42.7).
Multiple linear regression was used to evaluate the inﬂu-
ence of the sociodemographic and disease variables on
HRQL. Separate regression models were developed for
the eight dimensions of the SF-36 and the three WOMAC
dimensions. Table I shows the variables which were inde-
pendently signiﬁcant (using multiple linear regression coef-
ﬁcients). The variables retained in each of the models
explained between 21% and 40% (R2 adjusted) of the var-
iability of each HRQL dimension.
The factors that hadanegative impact (worse) onHRQL in-
cluded: female gender in the vitality (P¼ 0.02) and social
function (P¼ 0.04) dimensions of the SF-36 and the pain
(P¼ 0.04) and function (P¼ 0.04) dimensions of the
WOMAC; disease duration in the bodily pain dimension
(P¼ 0.01) of the SF-36; the number of comorbidities in the
general health (P¼ 0.01) and mental health (P¼ 0.02) di-
mensions of the SF-36; consumption of NSAIDs (7/week)
in the physical function (P¼ 0.02) and emotional role
(P¼ 0.02) dimensions of the SF-36 and the stiffness dimen-
sion (P¼ 0.02) of the WOMAC; and dissatisfaction with cur-
rent treatment in the pain dimension (P¼ 0.04) of the
WOMAC. In addition, a worse score in the self-perceived
health transition question was associated with worse HRQL
in all dimensions of the SF-36 and the WOMAC (P< 0.05).
In contrast, factors that had a positive (better) impact on
HRQL were: older age in the general health (P¼ 0.01)
and social function (P¼ 0.04) dimensions of the SF-36
and the pain (P¼ 0.02) and function (P¼ 0.04) dimensions
of the WOMAC; higher educational level, in the social func-
tion dimension (P¼ 0.04) of the SF-36; heavy lifting in the
physical function dimension (P¼ 0.01) of the SF-36; higher
family income in the emotional role dimension (P¼ 0.04) of
the SF-36; and no previous prostheses in the physical func-
tion (P¼ 0.04) and physical role (P¼ 0.04) dimensions of
the SF-36.
Table II shows the use and cost of economic resources
including medical visits, technical procedures and
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Fig. 1. SF-36 dimension scores expressed as mean values. Results were compared with (65e74 years) ageegender-matched Spanish RPVs.pharmacological treatment, hours of formal and informal
help during the 6 months previous to the study. Sixty-nine
per cent of patients visited a general practitioner, 40% a spe-
cialist, 26% other health care professionals and 5% alterna-
tive practitioners. Thirteen per cent of patients made no
medical visits. Six per cent of patients underwent blood
tests and 36% another technical procedure. Thirteen per
cent of patients took no drugs for their knee OA. Eighty-
three per cent of patients had some hours of help, but
only 3% received formal help.
Total mean direct medical costs were 200.24 V (95%CI
167.08e233.40) and total mean direct non-medical costs
were 1234.87 V (95%CI 812.74e1657.00).
With respect to the sociodemographic and disease vari-
ables, there was only a relationship between costs and
gender. Thus, mean rank direct medical costs were 54.46 V
for women compared with 40.79 V for men (P¼ 0.032).
Analysis of the relationships between total direct medical
and non-medical costs and the SF-36 and the WOMAC di-
mensions by the Spearman correlation coefﬁcient showed
low correlations (data not shown).
Discussion
The main objectives of this study were to evaluate the
quality of life of patients with severe knee OA included
on a WL for TKR, using the SF-36 and the WOMAC ques-
tionnaires3 and the use and cost of economic resources
related to knee OA. As in other studies3,22, we found
that these patients had substantially worsened HRQL,
measured by the SF-36, compared with general Spanish
RPVs3,14. In addition, when we compared the HRQL func-
tion and pain dimensions of our patients with the results of
other series, with a similar age but with no WL, we found
that in these series patients presented values that were
approximately 50% better for function (SF-36 and
WOMAC) and 15e20% for pain (SF-36)23,24. Furthermore,
in our patients, the perception of health had worsened in
the last year in more than half. The physical aspect of
HRQL was the most-affected (physical function, physicalrole and bodily pain dimensions of the SF-36 and function
dimension of the WOMAC)22.
Most of our patients had a high level of associated comor-
bidities, mainly cardiovascular and impaired sight; they
were overweight and almost half were obese3,12. Other
studies have also found an association between worse
HRQL and lower educational level12,25 and lower income25.
Hawker et al.26 also reported that women had more symp-
toms (worse scores on the WOMAC) and greater disability
(worse scores on physical function and vitality dimensions
of the SF-36), as in our study. As in other studies, we found
that a worsened perception of health in the last year, longer
disease duration, a greater number of associated comorbid-
ities and a greater consumption of NSAID were associated
with worsened HRQL24,25,27.
When the use of resources by these patients was ana-
lyzed, the results showed a surprisingly-low use of physi-
cian care, with most patients making only one medical
visit, generally to a GP. The low number of visits to special-
ists such as rehabilitative physicians is also surprising, as
reports have recommended physiotherapy to maintain cor-
rect muscular tone before interventions as a factor in better
postoperative recovery, due to the severe locomotor deﬁcits
present in OA28. Patients reported taking low doses of
NSAIDs and practically no analgesics, with no case comply-
ing with anti-inﬂammatory or analgesic guidelines (2400 mg
of ibuprofen or similar would correspond to 4 tablets per day
and 3e4 g/day of acetaminophen would correspond to 3e4
tablets)29, possibly because, in our patients, alterations in
physical function were more important than pain. Neverthe-
less, some evidence suggests that medications are often
prescribed at doses too low for optimal control of symp-
toms30. Jordan et al.8 reported that, in patients with a sub-
stantial impact of OA on HRQL, both pharmacological and
non-pharmacological treatments that can improve disease
symptoms are underused. However, none of our patients
had received any non-pharmacological treatments.
Less than half of the patients had undergone some te-
chnical procedure, mainly radiographies. Consequently,
their direct medical costs were very low, above all when
compared with other series11,31. In one patient, Magnetic
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Use and cost of economic resources related to knee OA
Resource Quantity of resources
used per patient
Cost of economic resources
used per patient (V)
Mean (95%CI) Mean (95%CI)
Direct medical
Number of visits to: (n)
General practitioner 2.42 (1.78e2.88) 79.8 (58.7e95.1)
Specialist 0.62 (0.41e0.83) 20.46 (13.63e27.28)
Other health care professionals: nurse practitioner 1.57 (0.81e2.33) 23.11 (11.95e34.26)
Alternative practitioners 0.09 (0.00e0.18) 2.16 (0.09e4.41)
Number of technical procedures: (n)
Conventional radiographic examinations 0.46 (0.25e0.67) 10.34 (5.59e15.09)
Magnetic resonance imaging 0.13 (0.06e0.20) 27.35 (12.04e42.65)
Other technical procedures 0.08 (0.03e0.13) 6.09 (1.54e10.64)
Blood test 0.12 (0.00e0.24) 2.52 (0.01e5.06)
Pharmacological treatment: (n tablets/week)* 15.38 (12.33e18.43) 31.34 (25.52e37.15)
Total 200.24 (167.08e233.40)
Direct non-medical
Hours of informal help (h) 129.82 (89.69e169.95) 908.76 (627.85e1189.66)
Hours of formal help (h) 43.20 (5.79e92.19) 302.40 (40.51e645.31)
Out-of-pocket expenses (V) e 23.71 (10.48e36.95)
Total 1234.87 (812.74e1657.00)
Total direct medical cost women/men (V): mean rank 54.46/40.79 (P¼ 0.032)y
Total direct non-medical cost women/men (V): mean rank 58.29/31.43 (P< 0.001)y
Costs are estimated at 2001 prices (V) (the accumulated increase in the retail price index of Catalonia during the years 2001e2006 is 20%);
n: number; h: hours; V: euros.
*Pharmacological treatment included analgesics, NSAIDs and other drugs related to knee OA.
yManneWhitney test.resonance imaging was carried out, which may indicate
a unnecessary waste of resources, as it is not justiﬁed in
most cases of OA, particularly when surgical disease is
present.
As reported by other studies11,31, the main costs incurred
by these patients were on non-medical resources, mainly as
a consequence of functional limitation and loss of auton-
omy. In a study on the economic burden of disabling hip
and knee OA, Gupta et al.11 concluded that costs increased
with the worsening of the health status and greater OA
severity and that the value of caregiver time accounted
for, on average, 40% of direct non-medical costs. In our
study, although in a different context, the cost of caregiver
time corresponded to almost 98% of direct non-medical
costs. Likewise, as in other studies, direct and non-medical
(mainly help from family and friends) costs were related to
gender, with women incurring a greater economic burden
associated with OA than men11,23. Out-of-pocket expenses
were low, probably because our patients reported incomes
between two or three times lower than that reported by
Gupta et al.11.
However, our results, besides showing the impact of
knee OA on the life of the patients, both in quality of life
and economic terms, seem to suggest indirectly that other
aspects of the therapeutic management of this group of pa-
tients should be reconsidered. Thus, some results, such
as the overweight and/or obesity of long evolution, the
low number of visits to physicians and other health pro-
fessionals, or the high use of only one pharmacological
treatment, suggest little compliance with knee OA manage-
ment guidelines. These emphasize the principal roles of
weight loss, exercises, physical therapy, or drugs combined
with non-pharmacological strategies to reduce disability and
pain in knee OA12,28,29. As Bradley stated32: ‘‘Unfortunately,there is also evidence that a minority of physicians counsel
their knee OA patients about exercise, and fewer than 50%
of physicians follow up on performance of exercise by pa-
tients who have been counseled. Why then, don’t physi-
cians devote more time, effort, and resources to knee
patient education, exercise instruction and follow up, and
weight control?. Perhaps what is needed is an evaluation
of the barriers to incorporation into clinical practice of these
fundamental components of knee OA management’’. Our
results seem to support these comments. We have not ob-
served, at least in our setting, the use of therapeutic strate-
gies, except pharmacological ones, which have been
shown to be useful in the treatment of knee OA8,29,32.
The study was carried out in a single tertiary center.
Therefore, the results are only representative of this partic-
ular group of patients and might vary in other geographical
areas. We were not able to contrast our results with those of
other Spanish studies as there are none. Thus, we com-
pared the results with other preoperative studies in coun-
tries with different health systems and cultures. In
addition, few studies have evaluated the costs of informal
care and thus our study may provide data of interest. How-
ever, signiﬁcant costs, such as the time spent on health
care visits, the quality of life or the costs borne by care-
givers, were not included and the relatively small number
of patients could inﬂuence the results of the cost-analyses.
Thus, our ﬁndings should be interpreted with care. This
study only provides data on one measurement of patient
variables. We are at present carrying out a larger study
with a follow-up of 5 years including these and other
patients.
The strengths of the study are that it provides data of in-
terest on patients included on a WL, which may be seen as
the frontier between conservative and surgical treatments
264 M. Nu´n˜ez et al.: Quality of life waiting list and costsand a cut-off point to measure the impact of the disease in
health terms. In addition, the study of costs clearly showed
that conservative treatments were underutilized in these pa-
tients and that this may lead to earlier and possibly unnec-
essary surgical interventions with a consequent increased
risk of future replacement joint surgery. The study is also
one of the few to study the cost of informal care and the ﬁrst
that we know of HRQL in patients on a WL, as well as being
the ﬁrst Spanish study of HRQL and health costs in this
group.
In summary, our results are similar to those of other stud-
ies11,31 that found that the burden attributable to knee OA,
both in quality of life and economic terms, falls mainly on
sufferers and their families. As stated by March et al.31,
greater attention paid to the physical function and the health
status before surgery could improve results and decrease
the costs from the patient’s perspective.
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